share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahatme Sandesh

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahatme Sandesh

CRISPR Therapeutics | 4：持股變動聲明-董事 Mahatme Sandesh
美股sec公告 ·  05/31 16:20
Moomoo AI 已提取核心訊息
In a recent transaction, Sandesh Mahatme, associated with CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The specific details regarding the number of shares involved, the nature of the shares, the transaction price, and the post-transaction holdings were not disclosed in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
In a recent transaction, Sandesh Mahatme, associated with CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The specific details regarding the number of shares involved, the nature of the shares, the transaction price, and the post-transaction holdings were not disclosed in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
在最近的一筆交易中，與CRISPR Therapeutics AG（CRSP）相關的桑德什·馬哈特梅於2024年5月30日執行了一筆股票交易。公告中未披露有關所涉股票數量、股票性質、交易價格和交易後持股量的具體細節。建議投資者注意交易日期，以了解對股票表現的任何潛在影響。
在最近的一筆交易中，與CRISPR Therapeutics AG（CRSP）相關的桑德什·馬哈特梅於2024年5月30日執行了一筆股票交易。公告中未披露有關所涉股票數量、股票性質、交易價格和交易後持股量的具體細節。建議投資者注意交易日期，以了解對股票表現的任何潛在影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息